The following report consists of a description and tentative interpretation of the pharmacologic actions of Tofranil t. As will be demonstrated, Tofranil is different from other antidepressant agents of current clinical interest insofar as it is neither a stimulant nor an amine oxidase inhibitor. It is also in many respects different from the structurally related phenothiazines.
In contrast to cerebral stimulants (methylphenidate and amphetamine) and amine oxidase inhibitors, Tofranil does not counteract the sedative effect of reserpine in mammals, although some antagonism seems to be noticeable in rodents. The loss of the conditioned avoidance-escape response induced by reserpine cannot be prevented by pretreating rats with Tofranil, However, some other signs of the typical reserpine symptomatology such as miosis, ptosis and diarrhea are transiently antagonized by Tofranil.
When Tofranil is administered to unanesthetized, paralyzed cats in the same dosage that induced the above-mentioned behavioral changes, the electrocorticogram shows a slowing of frequency and intermittent occurrence of spindles. These changes are first and predominantly noted in the parietotemporal and occipital leads, the fast activity over the sensory motor area being the last to show the change. Very characteristic is the alternation of the slow wave pattern with stretches Fig. 1 . Effect of Tofranil on electrocorticogram and activating response. Intact, unanesthetized cat under succinylcholine and artificial respiration. Bipolar recording from the suprasylvian gyrus. 1. The resting pattern is shown during control, interrupted by a stimulus to the mesencephalic reticular formation, lasting 3 seconds. Note: activating response outlasts the stimulus. 2. Represents record 5 minutes after injection of Tofranil, Note the higher amplitude and slower frequency of the spontaneous pattern. The reticular activating response does not outlast the stimulus as long as in the control record 1. 3 . Additional administration of 10 mg/kg Tofranil intravenously half an hour after the first injection shortens the activation pattern even more. The high-voltage slow waves are more pronounced.
"Research Division, Geigy Pharmaceuticals, New York. tTrade Mark. The generic name of this drug is imipramine. Its chemical designation is S-(3-dimethylaminopropyJ)-10, I1-dihydro-SH-dibenz (b,f) azepine hydrochloride.
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CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 4, 1959 of fast activity. The electrocorticographic activating response elicited either by direct electrical stimulation of the mesencephalic portion of the reticular formation or indirectly by stimulating the sciatic nerve is diminished but not abolished ( Fig. 1 ). Cortical potentials evoked by presentation of an auditory stimulus in the form of a single click or by single shock to the sciatic nerve are picked up unaltered or slightly enhanced in their respective sensory areas. The threshold for eliciting thalamo-cortical recruiting responses is not significantly altered. In a 'cerveau isole' preparation the prevailing sleep-pattern is maintained after administration of Tofranil.
The conditioned escape-avoidance response (1) is fully preserved after single subcutaneous injection of up to 60 mg/kg of Tofranil (Fig. 2 ), or after daily oral administration of 30 mg/kg for four consecutive days. This is in sharp contrast to chlorpromazine which leads to an almost total block of the conditioned response after injection of 10 mg/kg subcutaneously. Effect of Tofranil on the conditioned escape-avoidance response in rats. Rats were trained to jump to a pole in response to a buzzer (conditioned response) after having been reinforced to do so in 15 to 20 trials with electric shocks (1) . Ordinate: Proportion of group of rats which show the conditioned response. Abscissa: Dose in mg/kg, Tofranil potentiates the hexobarbital sleeping time of mice to a much lesser extent than chlorpromazine ( Fig. 3 ). Furthermore, it does not induce sleep in mice pretreated with a sub-hypnotic dose of ethyl alcohol, whereas chlorpromazine initiates long-lasting sleep in these animals ( Fig. 4) .
Temperature regulation is much better preserved under the influence of Tofranil than after administration of chlorpromazine. Thus, rectal temperature in mice is maintained near control values after intraperitoneal injection of 10 mg/kg of Tofranil whereas the same dose of chlorpromazine causes a marked fall in body temperature (Fig. 5 ).
The susceptibility to seizures evoked by electroshock or pentamethylenetetrazol is diminished by Tofranil. After injection of 10-30 mg/kg subcutaneously, Tofranil prevents the occurrence of the tonic phase of the typical seizure pattern in a significant percentage of mice subjected to maximal electroshock or pentamethylenetetrazol convulsions ( Table 1) . No significant influence, however, is noted on the fatal course of strychnine-induced seizures. On the other hand, chlorpromazine does not alter the various components of convulsions produced by pentamethylenetetrazol or electroshock. In cats with a high spinal transection the patellar reflex is often enhanced after the first injection of Tofranil. Subsequent administration of Tofranil generally fails to reveal any significant change either in mono-or poly-synaptic reflexes ( Fig. 6 ). Local anesthetic action can be demonstrated on the rabbit cornea, where insensitivity for 10-20 minutes is produced by topical application of a 1% solution of T ofranil. Electroshock was given through corneal electrodes at a current of 30 rnA for a duration of 0.2 seconds. Pentamethylenetetrazol was injected intravenously; 0.2 ml of 0.5% solution of Tofriinil was injected intraperitoneally 15 and 60 minutes prior to the induction of seizures. The table indicates the percentage of mice (in a group of twenty animals) which are protected from the tonic component of the full seizure pattern.
Peripheral autonomic, respiratory and cardiovascular effects. Tofranil in doses of 1-3 mg/kg intravenously does not affect the contraction of the nictitating membrane in response to maximal preganglionic stimulation of the cervical sympathetic nerve. However, higher doses diminish the contraction of the nictitating membrane to both pre-and post-ganglionic sympathetic stimulation to an equal. extent, thus indicating that transmission through sympathetic ganglia is preserved under the influence of Tofranil, Distinct anticholinergic properties are observed after intravenous administration of small doses (1-3 mg/kg) of Tofranil, Bradycardia and fall of blood pressure induced by stimulation of the peripheral end of the cut vagal nerve are diminished ( Fig. 7 ). Pilocarpine-induced salivation is reduced. Slight mydriasis develops. The effect of acetylcholine in producing spasm of the isolated intestine is also blocked ( Table 2) (2). Some of the side effects which are observed under clinical conditions, such as dry mouth, blurred vision, and constipation, can be explained on the basis of the above-mentioned findings. -.
Doses of Tofrarul and chlorpromazine producing an action equivalent to standard agents are indicated. Respiration in the anesthetized cat is invariably slowed ( Fig. 8-A) , and the changes in the respiratory reflex normally evoked by stimulation of the central stump of the cut vagal nerve are diminished ( Fig. 8-B ) as is the carotid occlusion reflex ( Fig. 9 ). In cats lightly anesthetized with pentobarbital, slow intravenous infusion of 1-3 rug/kg Tofranil causes a fall in blood pressure of 10-20%. The heart rate is usually not altered but in some instances it is slightly accelerated. Rapid injection of the same dose, however, produces a sharp drop in blood pressure of 40-50%, which cannot be prevented by atropine and/or vagotomy. In doses of 1-5 rng/kg intravenously Tofranil enhances and prolongs the vasopressor response of norepinephrine ( Fig. lO-A) . Repeated administration does not further enhance the potentiation. On the other hand, the pressor response to epinephrine is initially often reduced but returns subsequently to control values ( Fig. lO-B) . The rise in blood pressure produced by tyramine or amphetamine is diminished by Tofranil, The hypotension elicited in the anesthetized cat by injection of serotonin or histamine is distinctly less pronounced after administration of Tofranil, This accords with the finding that Tofranil relieves the contractions of isolated intestine induced VolA, 1959 --------
Innervated
---Ã by these two amines (Table 2) (2). The innervated and acutely denervated nictitating membrane reacts with enhanced retraction to norepinephrine after sensitization with Tofranil ( Fig. 11 ). Note: Both innervated and denervated nictitating membrane exhibit enhanced contraction in response to norepinephrine after administration of Tofranil,
Discussion
It is apparent that distinct differences exist between the pharmacologic properties of Tofranil and the structurally related phenothiazine (1, 3) . However, the data presented do not offer an explanation as to the mechanisms involved in the antidepressant action of Tofranil. The finding that Tofranil does not inhibit amine oxidase (4) indicates that amine oxidase inhibition is not a prerequisite for antidepressant action. In view of its effect on the peripheral adrenergic system the question arises whether Tofranil exerts its antidepressant effect by sensitization of central adrenergic synapses. Unfortunately, direct evidence for this hypothesis is 
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lacking. Increasing importance is now being attributed to adrenergic mechanisms operating at the level of the brain stem reticular formation. Thus adrenergic neurohumors, which are highly concentrated in the brain stem (5) , stimulate the ascending as well as the descending reticular system, producing cortical activation and facilitation of motor and spinal reflex activity (6) . A number of agents, most of them structurally related to catecholamines, produce central excitatory phenomena by acting on the epinephrine-sensitive component of the reticular formation (7) . Accumulation of adrenergic neurohumors, their metabolic disposal prevented by the presence of amine oxidase inhibitors (8) , leads likewise to an excitatory state. Conversely, depletion of adrenergic neurohumors (9) at their synaptic site (e.g. by reserpine), as well as blocking of their central action, leads to depression. In the light of these considerations it is tempting to speculate that a common denominator for antidepressant activity consists of an activation of central adrenergic mechanisms (Table 3) . 
Discussion
E. ROTHLIN* I appreciate very much the opportunity to participate in this conference where a new psychotropic drug (found by a Swiss firm) will find not its birth but as we say its fire-baptism.
From the foregoing reports we have learned some interesting and important concepts on the phenomenology, psychodynamics and terminology of depression and allied states. This is an impressive picture about the clinical aspects of the problem from the psychological and diagnostic-prognostic viewpoints.
·Professor of Pharmacology, University of Basle, and President, Collegium Internationale Neuro-Psycho-Pharmacologicum.
Vol. 4, 1959 With the reports on the chemistry and pharmacology of Tofranil by Dr. Hafliger and Dr. Sigg, to whom I express my best thanks for clearness and timing, we approach the problem from the experimental side. What do we expect from a pharmacological investigation? This should give the basis for clinical evaluation whose goal is to find out the correlations between the changes provoked by psychotropic drugs in human behavior with the alterations produced by such drugs in the neuronal processes in the brain.
Dr. Sigg endeavors to demonstrate the peculiar pharmacological properties of Tofranil by comparative investigation of the new compound with the classical tranquilizers chlorpromazine and reserpine on one hand and with the central stimulants like amphetamine and LSD on the other. Tofranil is less sedative than the tranquilizers mentioned and does not antagonize the sedative effects of reserpine, characteristics of amphetamine and LSD. But it counteracts cholinergic symptoms produced by reserpine like miosis, lacrimation and diarrhea, and this corresponds with the anticholinergic properties of Tofranil.
The most peculiar and selective finding of all the pharmacological tests seems to be the sensitizing effect of adrenergic functions. The data of the anticholinergic and adreno-sensitizing effects of Tofranil are partly experimental, partly clinical; partly peripheral, partly central. This is the basis of what Dr. Sigg calls the "antidepressant" activity of Tofranil, Antidepressive action can be a special kind of alertness or a reactivation of vital processes. It is most probable that this action is related to the autonomic regulatory functions of the brain stem. The localization of these processes only in the reticular formation seems to be too limited. To find out the selective and characteristic properties of Tofranil, a further and thorough study in the frame of experimental and clinical reference will be probably more reliable than the usual tendency of analogizing with other psychotropic drugs.
Anticholinergic and adreno-sensitizing actions are synergistic in their end-effect, and are outcomings of the general principle of the antagonistic operation of the autonomic nervous sytem in peripheral as well as central nervous functions. W. R. Hess already stressed the importance of autonomic representation in the brain stem and particularly in the hypothalamus for the regulation of autonomic functions in the peripheral effector organs as well as for the relationship between autonomic with somatic and psychic processes. This is the basis of the general concept of W. R. Hess of the ergotropic-trophotropic system which corresponds to the sympathetic and para-sympathetic divisions of the autonomic nervous system.
. In this connection I would draw attention to the findings and concepts of Gellhorn, of Funkenstein, Greenblatt and Solomon, and of Darrow and Hill. Gellhorn reports that the fall of blood pressure after mecholyl depends on the reactivity of the sympathetic-adrenal system in relation to the parasympathetic system. Weakness of sympathetic tonus (posterior hypothalamus) increases, weakness of the parasympathetic tonus (anterior hypothalamus) decreases the extent of the blood pressure drop by mecholyl in intensity and duration. Gellhorn carried out similar investigations with norepinephrine in order to examine the parasympathetic tonus (anterior hypothalamus) and found that the pulse-slowing reflex of norepinephrine is diminished when the tonus of the parasympathetic division is artificially reduced by local application of pentothal.
Many data suggest that the responsiveness of the autonomic centers in the brain stem plays a role in mental disorders, and Darrow and Hill show for instance that central sympathetic reactivity increases as the mental state of the patient improves.
These pharmacological investigations reveal that there are intimate correlations between the regulatory play of the central sympathetic and parasympathetic divisions and that a tonic change of these autonomic centers leads to imbalance of autonomic regulation in peripheral effector organs as well as in neural processes of psychic order.
With regard to the chemical aspects of Tofranil Dr. Hafliger showed the chemical relation of Tofranil and promazine and stressed the difference of the ring system, which suffices for the fundamental difference of pharmacological activity. It is worthwhile to mention that Tofranil and iproniazid are two chemically very different compounds, and yet both agents seem to display grosse modo similar clinical effects, and both are used in diverse states of depression. But the pharmacology of iproniazid and Tofranil seems to be very different with regard to tolerance and the course of action. The mode of action of iproniazid is as far as we know related to its inhibitory action on amine-oxidase. By that the oxidative destruction of catecholamines and of serotonin is inhibited, and this leads to a change in the balance of the so-called neurohumoral mediators, especially in the brain stem. The neurophysiological and biochemical mode of action of Tofranil is certainly different from that of iproniazid, but is still unknown. So we have an analogous situation for Tofranil and iproniazid on the one hand and for chlorpromazine and reserpine on the other. Both groups of psychotropic agents are chemically very different but grosso modo they produce similar clinical effects.
Yet the mode of action of the two representatives of each group is different too. This statement is of paramount importance because it demonstrates 1) the impossibility of drawing pharmacological and clinical inferences from chemical" constitution; 2) the difficulty of explaining behavorial changes produced by psychotropic drugs; 3) the ability to determine if these chemically induced effects are direct or indirect, specific or non-specific, in nature; and~) the complexity of psychopharmacological problems as a whole.
With a subject.iike psychopharmacology, in which so many divisions of research are involved and which expands so rapidly, it !s not astonishing that theories are flourishing. In this respect, Dr. Sigg is rather cautious. He describes his findings and brings them in relation to the theory of excitatory phenomena by an action "on the epinephrine-sensitive component of the reticular (ormation;" and he attempts to speculate "that a common denominator for 'anti-depressant' activity consists of an activation of central adrenergic mechanisms."
For the time being the psychopharmacological approach of Dr. Sigg is certainly a good working hypothesis, and corresponds to the above-mentioned concepts of W. R. Hess, Funkenstein et aI., Gellhorn, Darrow and Hill, and others.
While the many theories in psychopharmacology are good working hypotheses, proofs of scientific curiosity as well as of the need for integrating understanding, they must be taken as moves in a very great and complex game, the goal of which is to find definite correlations between the psychotropic influence of drugs in human behavior and the physiological, biochemical and psychologic changes produced by such drugs. This can only be reached by more objective experimental and clinical research, accompanied and encouraged by conceptual analysis of the findings.
General discussion from the floor (summarized)
It was brought out in discussion that electroshock and certain phrenotropic drugs such as chlorpromazine induce slow-wave EEG changes in man, while other phrenotropic drugs that are classified pharmacologically as anticholinergic drugs induce desynchronization changes in the EEG. Data were presented showing that Tofranil is similar in this respect to diethazine and benactyzine, which are known to have anticholinergic activity, and that its therapeutic effect might possibly be related to its anticholinergic activity. The possibility was also mentioned that the ability to diminish convulsive activity might be the common factor in somatic therapy of depression.
One discussant reminded the group that neither a chemical nor a pharmacological approach could have led to a prediction of the clinical effects of Tofranil, and that these were ultimately discovered by astute clinical observation. However, available methods should now allow us to clarify the manner in which catecholamines may be affected by various drugs. The speaker emphasized the importance of studies directed toward this question, and felt that it was therefore quite worth while to explore Dr. Sigg's suggestions concerning the mechanism of action of Tofranil,
